E
Kintara Therapeutics, Inc. KTRA
NASDAQ
Recommendation
Sell
Prev Close
$7.54
Volume
--
Avg Vol (90D)
143,054
Market Cap
$11.61M
Dividend & Yield
--
52-Week Range
$2.84 - $160.51
P/E (TTM)
--
EPS (TTM)
-$75.24
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Kintara Therapeutics Inc trading halted, news pending
10/17/2024 - TipRanks Financial Blog
Kintara Therapeutics Inc trading halted, news pending
10/17/2024 - The Fly
Kintara announces 1-for-35 reverse stock split in connection with TuHURA merger
10/16/2024 - TipRanks Financial Blog
Kintara announces correction to prior reverse stock split announcement
10/16/2024 - TipRanks Financial Blog
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024
10/16/2024 - PR Newswire
Kintara announces 1-for-35 reverse stock split in connection with TuHURA merger
10/16/2024 - TipRanks Financial Blog
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences
10/16/2024 - PR Newswire
Kintara Therapeutics corrects previous press release
10/15/2024 - The Fly
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
10/15/2024 - PR Newswire
Kintara Therapeutics Set for Strategic Merger and CVR Issuance
10/14/2024 - TipRanks Financial Blog
Kintara Therapeutics announces record date for CVR issuance
10/14/2024 - The Fly
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
10/14/2024 - PR Newswire
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update
10/8/2024 - PR Newswire
Kintara Therapeutics (NASDAQ:KTRA) Stock Price Down 6.3%
9/26/2024 - Ticker Report
Kintara Urges Shareholder Votes for TuHURA Biosciences Merger
9/24/2024 - TipRanks Financial Blog
Kintara Postpones Stockholder Meeting for Merger Decision
9/20/2024 - TipRanks Financial Blog
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024
9/20/2024 - PR Newswire
Kintara Announces Special Meeting for Proposed TuHURA Merger
9/19/2024 - TipRanks Financial Blog
Kintara Therapeutics Seeks Approval for Key Merger with TuHURA Biosciences
9/18/2024 - TipRanks Financial Blog
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences
9/18/2024 - PR Newswire
Kintara Therapeutics Advances with TuHURA Merger and Trials
9/11/2024 - TipRanks Financial Blog
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study
9/11/2024 - PR Newswire
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.
9/9/2024 - PR Newswire
Kintara Therapeutics Announces Special Meeting for TuHURA Merger
9/3/2024 - TipRanks Financial Blog
Kintara Therapeutics: Clinical Trial Resumes Amid Merger Uncertainties
8/19/2024 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$8.40M
EBIT (TTM)
-$8.45M
Net Income (TTM)
-$8.32M
Balance Sheet
Total Assets (Q)
$6.20M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$2.45M
Book Value Per Share (Q)
-$4.11
Cash Flow
Cash from Operations (TTM)
-$7.18M
Cash from Investing (TTM)
-$20.00K
Cash from Financing (TTM)
$10.57M
Net Change in Cash (TTM)
$3.37M
Filings
Filing Date
Monday, October 7, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Week of Nov 11 and 15 (est)
Price History
Loading...
Beta
-0.67
7-Day Total Return
15.87%
30-Day Total Return
23.86%
60-Day Total Return
-0.83%
90-Day Total Return
12.77%
Year to Date Total Return
35.56%
1-Year Total Return
-94.71%
2-Year Total Return
-95.70%
3-Year Total Return
-99.49%
5-Year Total Return
-99.11%
52-week Low
Mar 12, 2024 - $2.84
52-week High
Oct 19, 2023 - $160.51
Valuation
Market Cap
$11.61M - Nano Cap
Enterprise Value
$16.95M
Price/Sales (TTM)
--
Price/Book (Q)
-1.83
Dividends and Shares
Shares Outstanding
1.57M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.kintara.com
Phone Number
858 350 4364
Address
9920 Pacific Heights Blvd
San Diego, CA 92121
Country
United States
Year Founded
2009
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage... more
Weiss Ratings